The Democratic Republic of Congo has launched a large-scale clinical trial to evaluate an experimental treatment for the ongoing Ebola outbreak, marking a significant step in efforts to combat the deadly disease.
The study will assess the effectiveness of two investigational therapies against the Bundibugyo strain of the Ebola virus, a rare variant for which there are currently no approved vaccines or specific treatments. Health authorities said the trial will involve more than 1,000 patients and will compare the performance of an antibody-based treatment, MBP134, used alone and in combination with the antiviral drug remdesivir.
Participants will also receive standard supportive medical care throughout the study. The initiative is being coordinated by international health experts in collaboration with Congolese authorities and other research partners, with the aim of identifying a safe and effective treatment that can help reduce deaths from the outbreak.
The latest Ebola outbreak has infected more than 1,400 people and claimed hundreds of lives, raising concerns among global health authorities.
Despite challenges posed by insecurity and limited access to some affected communities, officials remain hopeful that the clinical trial will provide valuable data to strengthen the response to the disease and improve future treatment options.
